Astellas and seagen announce china's national medical products administration accepts biologics license application for enfortumab vedotin in certain patients with locally advanced or metastatic urothelial cancer

– clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with locally advanced or metastatic urothelial cancer who received prior treatment with a pd-1/l1 inhibitor and platinum-based chemotherapy – tokyo and bothell, wash. , march 9, 2023 /prnewswire/ -- astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d.
SGEN Ratings Summary
SGEN Quant Ranking